BridgeBio PharmaBridgeBio Pharma
BP

BridgeBio Pharma

Biopharmaceutical company developing transformative medicines for patients with genetic diseases and cancers.

Website
2015Active875
Advertise here

About

BridgeBio is a biopharmaceutical company focused on bringing meaningful medicines to patients quickly and safely. They develop and deliver treatments for genetic diseases, with a pipeline that includes approved medicines like Attruby® (acoramidis) and NULIBRY® (fosdenopterin), as well as investigational therapies for conditions such as Transthyretin Amyloidosis and Limb-Girdle Muscular Dystrophy. BridgeBio serves patients by advancing a diverse pipeline of therapeutic candidates from discovery through to commercialization.

Technology stack

detected 2026-06-18
Est. monthly stack spend~$1,830/mo
CDN
AWS CloudFront
EmailMicrosoft 365
Hosting
AWS
Analytics
Google Tag Manager
Cookie consent
OneTrust
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does BridgeBio Pharma do?

BridgeBio is a biopharmaceutical company focused on bringing meaningful medicines to patients quickly and safely. They develop and deliver treatments for genetic diseases, with a pipeline that includes approved medicines like Attruby® (acoramidis) and NULIBRY® (fosdenopterin), as well as investigational therapies for conditions such as Transthyretin Amyloidosis and Limb-Girdle Muscular Dystrophy. BridgeBio serves patients by advancing a diverse pipeline of therapeutic candidates from discovery t…

Where is BridgeBio Pharma headquartered?

BridgeBio Pharma is headquartered in Palo Alto, United States.

When was BridgeBio Pharma founded?

BridgeBio Pharma was founded in 2015.

What industry does BridgeBio Pharma operate in?

BridgeBio Pharma operates in Biotech, Pharmaceuticals, Healthcare.

How many employees does BridgeBio Pharma have?

BridgeBio Pharma has approximately 875 people on record.